These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 36255428)

  • 1. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
    Dusetzina SB; Huskamp HA; Qin X; Keating NL
    JAMA; 2022 Oct; 328(15):1515-1522. PubMed ID: 36255428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage.
    McWilliams JM; Zaslavsky AM; Huskamp HA
    JAMA; 2011 Jul; 306(4):402-9. PubMed ID: 21791689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
    Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P
    J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013.
    Krumholz HM; Nuti SV; Downing NS; Normand SL; Wang Y
    JAMA; 2015 Jul; 314(4):355-65. PubMed ID: 26219053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in Low-Value Health Service Use and Spending in the US Medicare Fee-for-Service Program, 2014-2018.
    Mafi JN; Reid RO; Baseman LH; Hickey S; Totten M; Agniel D; Fendrick AM; Sarkisian C; Damberg CL
    JAMA Netw Open; 2021 Feb; 4(2):e2037328. PubMed ID: 33591365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of Medicare Part D on drug and medical spending.
    Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
    N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sources of regional variation in Medicare Part D drug spending.
    Donohue JM; Morden NE; Gellad WF; Bynum JP; Zhou W; Hanlon JT; Skinner J
    N Engl J Med; 2012 Feb; 366(6):530-8. PubMed ID: 22316446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
    Park T; Jung J
    J Manag Care Spec Pharm; 2017 Jan; 23(1):5-12. PubMed ID: 28025927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Effects of Pioneer Accountable Care Organizations on Medicare Part D Drug Spending and Utilization.
    Zhang Y; Caines KJ; Powers CA
    Med Care; 2017 May; 55(5):470-475. PubMed ID: 28060052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
    DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
    JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Medicare Accountable Care Organization Implementation and Spending Among Clinically Vulnerable Beneficiaries.
    Colla CH; Lewis VA; Kao LS; O'Malley AJ; Chang CH; Fisher ES
    JAMA Intern Med; 2016 Aug; 176(8):1167-75. PubMed ID: 27322485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of Intensive Lifestyle Intervention in Type 2 Diabetes With Health Care Use, Spending, and Disability: An Ancillary Study of the Look AHEAD Study.
    Huckfeldt PJ; Frenier C; Pajewski NM; Espeland M; Peters A; Casanova R; Pi-Sunyer X; Cheskin L; Goldman DP
    JAMA Netw Open; 2020 Nov; 3(11):e2025488. PubMed ID: 33231638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Pioneer Accountable Care Organizations vs traditional Medicare fee for service with spending, utilization, and patient experience.
    Nyweide DJ; Lee W; Cuerdon TT; Pham HH; Cox M; Rajkumar R; Conway PH
    JAMA; 2015 Jun; 313(21):2152-61. PubMed ID: 25938875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in health care spending and quality for Medicare beneficiaries associated with a commercial ACO contract.
    McWilliams JM; Landon BE; Chernew ME
    JAMA; 2013 Aug; 310(8):829-36. PubMed ID: 23982369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
    Hayford TB
    JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
    Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
    BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuity of Care and Health Care Utilization in Older Adults With Dementia in Fee-for-Service Medicare.
    Amjad H; Carmichael D; Austin AM; Chang CH; Bynum JP
    JAMA Intern Med; 2016 Sep; 176(9):1371-8. PubMed ID: 27454945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.